Salmonella enterica contaminating food products is the main cause of deaths due to bacterial enteric infections in USA and worldwide. NOMAD product candidates described and claimed in the patent application are one or more Salmocins applied at very low doses; the products are highly and broadly active against all major pathogenic Salmonella strains causing food poisoning and clinical infections. NOMAD is aggressively filing for patent protection of all its inventions related to bacteriocins as precision biologics to be used as medicines and food/feed additives.

NOMAD is developing bacteriocins primarily as medical alternatives to antibiotics, with its pre-clinical research focusing on novel antibacterial proteins for control of major multi-drug resistant Gram-negative pathogens including Escherichia, Pseudomonas, Klebsiella and Salmonella. We plan to enter clinical trials of our product candidates by 2022.

Salmocins and other bacteriocins are being also developed by NOMAD as food additives and food processing aids for the broad control of most common bacterial pathogens (Escherichia coli, Salmonella enterica and Clostridium perfringens) in food products.

‘We are very pleased that USPTO has allowed all essential claims in our application’, said Prof. Dr. Yuri Gleba, NOMAD’s CEO. ‘Our Salmocin product candidates have also received GRAS manufacturing regulatory registrations in USA from FDA as food processing aids (GRN 824) and registered by USDA (FSIS 7120.1). Nomad has by now eight successful FDA GRAS registrations, and we are in the process of securing regulatory approvals in other major countries. These approvals, together with the broad patent protection and exclusivity resulting from the USPTO decision, significantly strengthens NOMAD’s position as the leading provider of novel safety solutions for medicine, veterinary and food/feed markets.’